Skip to main content

Autoinflammatory

lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter

Read Article
New Download Available! AOSD Disease Patterns Over Time https://t.co/IYePF20Nkn https://t.co/fOnc6jUl1b
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
Flare Patterns in Autoinflammatory Syndrome During Pandemic: Dr. Yuz Yusof ( @Yuz6Yusof) discusses abstract #1083 presented at the #ACR21 annual meeting.https://t.co/i0VU3NEe7F https://t.co/DZkB5TgG3N
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares Drs.Cush, Yusof, Mehta, Petryna and Tate review autoinflammatory data presented at #ACR21. @Yuz6Yusof @bella_mehta @DrPetryna @uptoTate https://t.co/oeAprkSBWZ https://t.co/1g9yRRFJqf
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
#ACR21 is complete--view all our RheumNow's coverage.https://t.co/wkZ66lcB44

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021
Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush reviews poster #1100 presented at the #ACR21 annual meeting.https://t.co/2YGPHT3AAO https://t.co/lLRKnxB04a
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Sign

Emapalumab for the treatment of macrophage activation syndrome

Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

Nov 10, 2021

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 09, 2021
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21.https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA ⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful ⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC ⭐️Ok to continue IL1i ▶️13/14 pts remission ▶️ SAEs: 1 CMV reactivationhttps://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC
Nov 09, 2021
Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062
Nov 09, 2021
#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
Emapalumab (IFNg inhibitor) Effective in severe MAS (Ferritin 25K, failed anakinra, GC)- 14 pts (2-25 yrs; 4/14 sJIA)-13/14 remission, w rapid drops in CXCL9, Ferritin, ALT, DDimers & GC dose #ACR21 ABst LB20 https://t.co/05oW5C8Waf https://t.co/ecEkt3MY83
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
rare

Risks associated with mortality in VEXAS

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition. One

Read Article
Telemedicine

Telemedicine Enriched Care Model for Autoinflammatory Diseases

Traditionally telemedicine is thought to be a technology where a patient directly talks to a provider or a specialist; however, another concept of having a patient with a local primary care who in turn accesses specialists via video conferencing, is gaining some momentum.  

Read Article
The plague protection genetically can lead to Pyrin induced inflammasome activation. Theory of more FMF in Mediterranean / Turkey. So high protection gene in population Dan Kastner - a genetic detective 9T119 #ACR21 #ACRBest @RheumNow https://t.co/qzdc12fT0j
Nov 09, 2021
Genes for oral aphthous ulcers common in gen pop’n, Behcets and w auto inflammatory PFAPA - kids w fevers ⬆️IL12 Kastner practical gene stories @RheumNow #ACR21 9T119. Have a listen. Bench to bedside & back https://t.co/UkPzoYbBNb
Nov 09, 2021
New dimensions in cellular immunology. Great session, some which I understood. Kids with #JIA have more cytolytic pathway missense - some leads to macrophage activation syndrome #MAS Low NK cells in Juvenile Dermatomyositis. 9T112 #ACR21 @RheumNow https://t.co/5lUkqr65UM
Nov 09, 2021
Abst1632 #ACR21 #ACRBest @RheumNow 25 children w/ uSAID & MEFV mutations: E148Q mutation standouts-32% heterozygous for E148Q, Asian ancestry seen in 37% kids w/ E148Q. E148Q assoc w/longer febrile episodes& less likely to have a full response to colchicine (25% vs 70%; p = 0.03) https://t.co/Rst6KHntPD
Olga Petryna @DrPetryna( View Tweet )
Nov 09, 2021
#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
ACR Best

ACR21 Best Abstracts We Saw - Day 3 (Monday)

Nov 08, 2021

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

Read Article
Telemedicine for AID patients! A fortunate pandemic outcome that PCPs shared "local" care benefit of specialists for these patients due to telemed. Abs 1062 #ACR21 @RheumNow #RheumNow https://t.co/zb0kZbzxsK

Dr. Rachel Tate @uptoTate( View Tweet )

Nov 08, 2021
×